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Abstract
Background: Adherence to pharmacological therapy is a complex and multi-factorial issue that can substantially
alter the outcome of treatment. It has been shown that cancer patients, especially when using long-term
medication, have similar adherence rates to those of patients with other diseases. The consequences of poor
adherence are poor health outcomes and increased health care costs. Only few studies have focused on the use of
oral anticancer agents in daily practice. Information about the reasons for non-adherence is essential for the
development of interventions that may increase adherence. This paper presents the CAPER-erlotinib protocol,
which is designed to study the relationship between adherence to erlotinib and both the plasma concentration
and side-effects in patients with NSCLC. Further, the relationships between patient characteristics, disease
characteristics, side-effects, quality of life, patient beliefs and attitude towards disease and medication, dose
adjustments, reasons for discontinuation and plasma concentration of erlotinib will be explored.
Methods/Design: In this prospective observational cohort study 65 NSCLC patients of 18 years or older starting
treatment with erlotinib will be followed for a period up to 16 weeks. The main study parameters are adherence,
the plasma concentration of erlotinib and the number and grade of side-effects. At baseline and on erlotinib
treatment in weeks 3-4, 8-9, 12 and 15-16, patients will be asked to fill out a questionnaire. In weeks 3-4, 8-9 and
15-16 blood samples are collected, which will be analysed for plasma concentration of erlotinib. Adherence will be
measured using a medication event monitoring system.
Discussion: The present study aims to get more insight into patients’ experiences with the use of erlotinib in daily
practice and the various aspects that govern adherence. We hypothesize that side-effects play an important role in
the way patients use erlotinib. We expect that the present study will provide valuable knowledge which will be
useful for health care professionals to develop interventions to support patients. This approach will improve the
adherence and persistence with the use of erlotinib in order to derive optimal benefit from the medication.
Trial Registration: NTR1830
Background
In the pharmacological treatment of cancer intravenous
(IV) therapy has played an important role. Since the last
decade a growing number of oral substances has been
introduced in cancer treatment. Most patients prefer
oral use of anticancer agents as long as it does not com-
promise the outcome of treatment [1,2]. In addition, the
overall costs of oral treatment are often lower than
those of IV therapy [3-5]. However, with the use of oral
medication at home in daily practice the issue of adher-
ence needs to be considered.
Adherence
Adherence to oral pharmacological therapy is a complex
and multifactorial issue that can substantially alter the
outcome of therapy [6,7]. Adherence (synonymous with
compliance) has recently been defined by the Interna-
tional Society for Pharmacoeconomics and Outcome
Research (ISPOR) as the extent to which a patient acts
in accordance with the prescribed interval and dose of a
dosing regimen [8]. A patient is optimally adherent if no
doses are missed, no extra doses are taken, and no
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doses are taken in the wrong quantity or at the wrong
time. Adherence is measured over a period of time and
reported as the adherence rate, which is the percentage
of dose taken in relation to what was prescribed [9].
There are several methods to measure adherence,
including self reports, pill counts, electronic monitoring
systems, analyses of pharmacy dispensing databases or
assessment of blood or urine samples. There is no
golden standard measurement and all methods have
limitations [9,10]. The major limitation of measuring
adherence is the so called Hawthorne effect: the measur-
ing of adherence itself influences the adherence because
the awareness of patients that adherence is being mea-
sured may influence their behaviour. Adherence rates
for many chronic drug therapies have been shown to
range between 35-70% [11]. The consequences of poor
adherence are poor health outcomes and increased
health care costs [6].
Adherence in oncology
Cancer patients are generally thought to have higher
adherence rates than other patients because they are
highly motivated by the gravity of their disease [12,13].
However, it has been shown that cancer patients have
similar adherence rates to those of patients with other
diseases [9,14,15]. Treatment duration plays a role in
the adherence to the regimen. When the medication is
continued over a longer period of time, patients become
less adherent [16].
In oncology adherence has been studied mainly in two
subpopulations, both using long-term medication. In the
first population, breast cancer patients on adjuvant hor-
monal therapy like tamoxifen the adherence rate has
been subject of several studies [9]. The reported adher-
ence rates range from 50% to 98% [13,16,17]. Several
studies concerning adherence to oral medication have
been published in the second subpopulation, patients
with Chronic Myeloid Leukemia (CML) [15,18,19]. Non
adherence appear to be associated with poorer response
to imatinib [15,18]. Noens et al have shown that patients
with suboptimal response had higher percentages of
imatinib not taken (23%) than those with optimal
response (7%). Marin et al have demonstrated in CML
that there was a strong correlation between adherence
rate and response. Adherence was the only critical factor
for achieving molecular response.
Another frequently overlooked problem is over-adher-
ence. This may be more an issue in oncology patients
than in other patients and may, in the case of oral antic-
ancer agents, lead to substantially increased toxicity [10].
In the study by Nilsson et al. [14], 30% had an oversup-
ply of their medication.
Oncologists may not always consider the issue of
adherence. Yet, suboptimal adherence may prove to be
the greatest barrier to the effective use of new oral
agents [9,18].
Causes of non-adherence
Several factors have shown to be associated with non-
adherence. These include patient variables like demo-
graphic factors, patients beliefs, disease variables, various
aspects of treatment regimes, side- effects and quality of
life.
The common sense model of self-regulation (CSM)
developed by Leventhal et al [20] is a commonly used
theoretical model to understand patients perceptions of
illness. According to the CSM peoples’ perception of
and beliefs about their illness is an important factor in
their reactions and behaviour to health threats. Illness
perceptions can easily be measured with the Brief Illness
Perceptions Questionnaire (Brief IPQ) [21].
Another factor which may influence adherence is
patients beliefs about the medication. These representa-
tions are usually determined with the Beliefs about Medi-
cine Questionnaire (BMQ) [22]. Associations between
adherence and BMQ scores have been shown[23-27].
Few studies have focused on patients’ reasons for not
adhering to oral anticancer agents. Eliasson et al [28]
have reported that finding ways to deal with the side-
effects leads to better adherence in patients with CML.
In clinical trials adverse events are generally reported by
clinicians, e.g. the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (CTCAE).
Basch et al have shown the value of patients’ reported
adverse symptom events in cancer patients, which better
reflect their daily health status [29,30].
Erlotinib
Erlotinib (Tarceva®) is an oral anticancer agent, which is
registered for the second- and third-line treatment of
NSCLC since 2006 [31] Erlotinib is a tyrosine kinase
inhibitor (TKI) of epidermal growth factor receptor
(EGFR-TKI).
Diarrhea and skin rash are the most common side-
effects of erlotinib. The incidence and severity of diar-
rhea seems to be related to the schedule and dose of
erlotinib [32]. Rudin et al [33] have not observed a rela-
tionship between the Area Under the Curve (AUC) con-
centration and diarrhea. However, they did find a
relationship between trough plasma concentration
(Ctrough) of erlotinib and skin rash. Hidalgo et al [32]
also detected a relationship between AUC and skin rash.
Interestingly, patients who experienced skin rash had
significantly longer survival [34,35].
Pharmacokinetics
Hidalgo et al [32] have suggested that an erlotinib
plasma concentration of 0.5 μg/ml would be sufficient
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for relevant antiproliferative activity. Peak concentrations
(Cmax) of erlotinib of 1.737 ± 0.777 μg/ml are reached
2.44 ± 1.94 hour (Tmax) after administration of 150 mg a
day. Erlotinib has a plasma volume of 233 L and is for
95% bound to plasma proteins like albumine and a1-
acid-glycoprotein. The plasma elimination half-life is
approximately 36 hours [36]. Erlotinib is mainly metabo-
lized by the liver (90%), only a small part is excreted by
the kidneys (9%). It is primarily metabolized by cyto-
chrome P450 3A4 (CYP3A4) and in a lesser extent by
CYP1A2, It is a substrate of the multi-drug transporter
ATP-binding cassette transporter ABCG2 [37].
Several drug interactions, smoking and food may
influence plasma concentrations of erlotinib. Drugs
that increase the pH of the upper gastrointestinal tract
may alter the solubility of erlotinib, thereby reducing
its bioavailability. Inhibitors or inducers of CYP3A4
and CYP1A2 influence the metabolism of erlotinib,
which may result in increased or decreased plasma
concentrations [31] Smoking results in a significantly
lower plasma concentration [38]. When erlotinib is
taken together with food the bioavailability of erlotinib
increases almost two-fold [39]. It is therefore advised
by the manufacturer to take erlotinib at least one hour
before or two hours after a meal [31]. Serum total
bilirubin, serum a1-acid glycoprotein, serum albumin,
creatinine clearance and gender are significant co-vari-
ables that explain interindividual variability for clear-
ance [36].
Objectives
The primary objective is to get insight into the relation-
ship between adherence to erlotinib and the plasma
concentration of erlotinib and the relationship between
adherence and side-effects in patients with NSCLC.
Furthermore, the relationships between patient charac-
teristics, disease characteristics, side-effects, quality of
life, patient beliefs and attitude towards disease and
medication, adherence, dose adjustments and plasma




A multicenter, prospective observational cohort study in
which patients starting treatment with erlotinib will be
followed for a period up to 16 weeks. At baseline and in
weeks 3-4, 8-9, 12 and 15-16, patients will be asked to
fill out a questionnaire. Furthermore, in weeks 3-4, 8-9
and 15-16, blood samples are collected, which will be
analysed for plasma concentration of erlotinib. Adher-
ence will be measured using a medication event moni-
toring system (MEMS). Information from the physician
will be retrieved from the patient treatment file.
Ethics
The protocol was approved by the Medical Ethics review
board of the VU University Medical Center, Amsterdam,
The Netherlands.
Recruitment and consent
Patients will be recruited by the Departments of Pulmo-
nalogy from twelve hospitals in the Netherlands. After
the patient and doctor have decided on treatment with
erlotinib, patients will be informed about the study and
will receive written information to take home. Within
two days the researcher will contact the patient by
phone to further inform the patient of the study and to
ask for his/her consent. If the patient decides to partici-
pate in the study, he or she will sign the informed
consentform.
Inclusion criteria
Patients with advanced NSCLC under treatment in one
of the participating hospitals starting with the use of
erlotinib can be included. Patients younger than 18
years and those with insufficient knowledge of the
Dutch language will be excluded. According to the sam-
ple size calculation (see Statistics) a number of 65
patients will be enrolled.
Measurements
Several methods are used to determine the variables.
Most information is collected directly from patients:
they will fill out questionnaires, will use an electronic
monitoring pill-container and will donate blood samples.
Furthermore, medical information will be retrieved from
the patients’ file.
Questionnaires
The patients will be asked to fill out five questionnaires
spread over 16 weeks. The first questionnaire (t = 0)
contains questions on patient characteristics, smoking,
co-medication, side-effects, quality of life, and patients
beliefs and attitude towards disease and medication. In
weeks 3-4, 8-9 and 15-16 patients will be asked to fill
out an elaborate questionnaire containing questions
determining the adherence behaviour, side-effects, dose
adjustment, co-medication, quality of life, and patients
beliefs and attitude towards disease and medication. In
week 12 patients are asked to fill out a short question-
naire containing only questions determining the adher-
ence behaviour, side effects, and dose adjustment.
Discontinuation and reasons for discontinuation will be
asked in a short questionnaire when a patient stops the
erlotinib treatment prematurely.
The questionnaires contain the following items:
1. MARS (Medication Adherence Report Scale)
[40,41]. This questionnaire contains statements about
adherence behaviour.
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2. Nature and grade of the side-effects in a five-point
scale.
3. Quality of life measured with SF-12 Health Survey
[42,43]. The SF-12 is a short version of the SF-36 and is
a validated method to measure quality of life.
4. Attitude towards disease measured with Brief Illness
Perception Questionnaire (Brief IPQ) [21]. The Brief
IPQ is a validated method to measure the attitude
towards disease.
5. Beliefs and attitude towards medicines measured
with Beliefs about Medicines Questionnaire (BMQ) [22].
The BMQ is a validated questionnaire. It is divided in
two parts, the BMQ general and the BMQ specific.
BMQ general measures the patient’s beliefs and attitude
towards medicines in general. The BMQ specific is spe-
cified for erlotinib.
6. Patient characteristics: date of birth, gender, socio-
economic status and smoking (current smoking and
never/previous smoking).
7. Dose adjustments by the patient. Dose adjustments
introduced by the doctor will be derived from the
patient file.
8. Co-medication.
9. Discontinuation and reasons for discontinuation.
Discontinuation is also derived from the patient file.
Electronic monitoring system
Adherence will be measured using a medication event
monitoring system (MEMS) [44]. Electronic monitoring
systems use standard pill containers with a small elec-
tronic processor in the cap, to record the timing and
frequency of bottle openings. Compared to other meth-
ods (e.g., assay, self-report, collateral report, prescription
refills), electronic monitoring captures more of the
dynamics of medication-taking behaviour [45]. In this
study the Evalan Real Time Medication Monitoring
(RTMM) is used.
Patient file
The following items are derived from the patient treat-
ment file.
• Disease characteristics like disease stage and line of
treatment.
• Dose adjustments
• Discontinuation and reasons for discontinuation
Blood sample and laboratory test
A plasma sample will be collected at visits of the patient
at week 3-4, 8-9 and 15-16. This blood sample will be
drawn simultaneously with the regular treatment’s
related blood sampling. At these visits patients are asked
when they had their last meal and at what time they
took their last erlotinib medication. Patients are sup-
posed to take erlotinib at least one hour before or two
hours after a meal [31]. Adherence to the instruction
will be taken into account in the analysis of the study
results.
Apart from that, the time of the blood sample will be
documented. Plasma concentrations of erlotinib will be
analyzed by LC-MS/MS. The pharmacokinetic para-
meters AUC, Cmax and Cthrough will be derived using the
pharmacokinetic model as described by Lu et al [36].
The concentration ratio (CR) is defined as the measured
erlotinib concentration divided by the mean population
erlotinib concentration that is predicted by the model.
To calculate the AUC, Cmax, Cthrough and CR the follow-
ing covariates are measured and used as input for the
model: gender, serum albumin, serum total bilirubin,
serum a1-acid glycoprotein, calculated creatinine clear-
ance and smoking status [36]. The calculated AUC,
Cmax, Cthrough and CR will be compared with the data
on adherence from the questionnaires and the electronic
monitoring system to study the relationship between
adherence and the plasma concentration of erlotinib.
Patients are asked about their co-medication in the
questionnaires. The data on co-administration of inhibi-
tors of CYP1A2 and CYP3A4, inductors of CYP3A4 and
antacids will be examined as covariables.
Statistics
The data will be described by means of frequency analy-
sis. Correlation coefficients will be calculated for rela-
tionships between adherence, patient characteristics,
disease characteristics, side effects, quality of life, patient
beliefs and attitude towards disease and medication,
dose adjustments and plasma concentration of erlotinib
in patients with NSCLC. In particular, the correlation
coefficient between plasma concentration and side-
effects; the relationship between dose and plasma con-
centration in daily practice; the influence of different
factors on adherence; the influence of different factors
on side-effects; the influence of different factors on
quality of life; the influence of different factors on dose
adjustment and discontinuation. By the use of a multi-
variate regression analysis the influence of adherence
(dependent variable) on plasma concentration and the
influence of side-effects (dependent variable) on adher-
ence will be calculated. The dependent variables will be
adjusted for potential confounders. For all analyses a
two-tailed significance level will be 0.05, all p values
below this level will be considered statistically signifi-
cant. The statistical analyses will be performed with
SPSS 15.0 (SPSS Inc. Chicago, Illinois, USA).
Discussion
The present study aims to get more insight into
patients’ experiences with the use of erlotinib in daily
practice. We expect variability in the adherence in the
general oncology population. This may be complicated
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by the inter-patient variability in the pharmacokinetics.
We hypothesize that side-effects play an important role
in the way patients use erlotinib. Therefore, the relation-
ship between self-reported side-effects and adherence is
also defined as a main objective. To get more insight
into other factors related to adherence and other aspects
of the use at home, the effects of determinants are stu-
died in an explorative manner.
We expect that the present study will provide valuable
knowledge on patients’ experiences with the use of erlo-
tinib. This knowledge will be useful for health care pro-
fessionals to develop specific interventions to support
patients thus improving the adherence and persistence
with the use of erlotinib in order to derive optimal ben-
efit from the medication.
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